Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

Eli Lilly joins FDA lawsuit over tirzepatide shortage listing, as Outsourcing Facilities Association challenges removal of ...

Eli Lilly has asked to intervene in litigation between a compounding pharmacy trade group and the FDA over the agency’s ...

In a statement to PEOPLE, an Eli Lilly spokesperson said, "FDA’s decision reiterating that the tirzepatide shortage is resolved reflects the tireless work of our manufacturing and quality ...

Following the FDA’s reaffirmation, 503B compounding pharmacies have until March 19 to stop selling compounded tirzepatide. In its motion filed on New Year’s Day, Eli Lilly stated it seeks to ...

Eli Lilly is joining in a lawsuit filed by the Outsourcing Facilities against the FDA, aiming to reverse the FDA's October 2024 determination that the shortage has been resolved, which would allow ...

Lilly seeks to protect interests in compounded drug case FDA affirms no shortage of tirzepatide drugs Compounded versions cheaper, often not covered by insurers Jan 2 (Reuters) - Eli Lilly (LLY.N ...

Amid new worries that legal copycats of the weight-loss drugs from Eli ... pen pay out of pocket depends on their insurance. For patients whose commercial coverage doesn’t cover Zepbound, Lilly ...

An age-old battle in pharmaceuticals could further rattle Eli Lilly ... and tirzepatide — are usually tied to gastrointestinal side effects. "If they're forced to go back to a pen (with the ...

According to a recent release from GlobalData, Eli Lilly’s obesity offering could become a potential leader in the market.